

PRESS RELEASE



CytoTools

Following a successful capital increase, CytoTools AG is set to expand the clinical development of *DermaPro*[®]

- Total of 170,000 new shares placed at issue price of EUR 21.80
- Gross issue proceeds of around EUR 3.7 million secures expansion of clinical studies in further indications for wound healing agent *DermaPro*[®]
- Further Phase IIb trials on chronic and acute wound treatment to be initiated this year

Darmstadt, 6 March 2013 – CytoTools AG, a technology holding with interests in the pharma and medical product sector, has successfully placed a capital increase of around 10%, using some of the authorised capital excluding the subscription right. The 170,000 new shares were subscribed exclusively by institutional investors at an issue price of EUR 21.80. They will be included in trading from 6 March 2008. The company is using its new funds to underpin the expansion of its clinical trials to two further indications for the wound healing agent *DermaPro*[®], which is currently in its final clinical phase III in Europe and India. CytoTools AG has used this capital increase to consolidate its financial basis and set the course for a significant enlargement of the potential target group.

Based on the issue proceeds as well as accompanying capital measures in subsidiary DermaTools Biotech GmbH, the potential of the *DermaPro*[®] can now be harnessed to a greater extent. CytoTools is imminently planning further clinical trials on the product, which is currently being tested both in Europe and India for the indication of diabetic foot, significantly expanding the treatment options as a result. "Previous trials have already confirmed the potential effectiveness of *DermaPro*[®] in other chronic wounds. *DermaPro*[®] showed healing potential for infected wounds in particular. The additional Phase IIb trials for *ulcus cruris* ("venous ulcer") will open up the successful development of the agent in the main indications of chronic and acute wound treatment even further," explains Dr. Kaiser, CEO of CytoTools AG. It will bring DermaTools closer to its strategic goal of being able to offer a comprehensive and all-round wound management system for the principal dermatological problems.

"Institutional investors asked us about investment opportunities in our company, which we have now created through this capital increase. We see the high level of demand as a big vote of confidence in our successful work and the promising development pipeline of our holding company," says Dr. Freyberg, CEO of CytoTools AG, explaining further reasons for the capital increase.

With DermaTools already having proved its successful treatment possibilities for the most serious chronic wound, diabetic foot, based on its current and earlier trials in Europe and India, the new trials will show the considerable additional potential of the globally patented substance. Dr. Freyberg is optimistic: "Along with the ongoing Phase III trials on diabetic foot in Europe and India, the results will substantially boost the project value." Despite possible minor delays in the submission of the trial results in India, an application for certification for the Indian market is expected this year. The company is also planning to carry out an interim assessment this year of the European Phase III trial for diabetic foot, which is currently underway. The launch of the new

PRESS RELEASE



CytoTools

Phase IIb trials researching further indications completes the picture and demonstrates the huge potential of *DermaPro*[®].

This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: approx. 60% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
64285 Darmstadt, Germany
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press contact:

cometis AG
Ulrich Wiehle
Unter den Eichen 7
65195 Wiesbaden, Germany
Tel.: +49-611-205855-11
Fax: +49-611-205855-66
E-Mail: wiehle@cometis.de